Video Shorts

1:04

How Butyrate Loss Affects Post-Transplant Outcomes in Myeloma

6 months ago

Pooja Phull, MD

1:03

Could Zanidatamab Replace Trastuzumab As the Gold Standard in First-Line HER2+ Gastric Cancer?

6 months ago

Manish A. Shah, MD

0:34

Role of Bridging Therapy Before CAR T-Cell Therapy in Myeloma

6 months ago

Matthew J. Frigault, MD

1:34

The Importance of HPV Vaccination in Oncology

6 months ago

Maurie Markman, MD

1:09

The Significance of the FDA Approval of Subcutaneous Daratumumab for Smoldering Multiple Myeloma

6 months ago

Peter Voorhees, MD

Laura Alder, MD, Eric K. Singhi, MD, and Paolo Tarantino, MD, PhD.

2:01

Quick Takes: Bridging the Gaps in Brain Mets, Continued

6 months ago

Paolo Tarantino, MD(+2 more)

0:51

Unpacking Real-World Data in mCRC

6 months ago

Rocio Garcia-Carbonero, MD, PhD

Jason Mouabbi, MD, Manmeet Ahluwalia, MD, MBA, FASCO, Laura Alder, MD.

1:45

Quick Takes: Bridging the Gaps in Brain Mets

6 months ago

Jason Mouabbi, MD(+2 more)

1:58

Lingering Questions on the Earlier Use of Oral SERDs in ER+ Breast Cancer

6 months ago

Seth Wander, MD, PhD

1:02

Dr Singhi on the Emerging Role of TROP2-Directed ADCs in the Evolving Treatment Algorithm of NSCLC

6 months ago

Eric K. Singhi, MD

1:04

Clinical Decision-Making Around Local vs Systemic Therapy for Metastatic Lung Cancer With CNS-Only Disease

6 months ago

Laura Alder, MD

1:10

Patient-Level Clinical Trial Communication Skills For Hematology/Oncology Fellows

7 months ago

Carma L. Bylund, PhD

1:52

ASCO GI 2026 Highlights

7 months ago

0:45

The Use of Measurements in Oncology to Define Clinical Utility

7 months ago

Maurie Markman, MD

0:57

FDA Approval of Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC

7 months ago

Christof Vulsteke, MD, PhD

1:09

AI-Powered Tools May Accelerate Developments in Precision Oncology for GI Cancer

7 months ago

William A. Hall, MD

0:50

Anderson Underscores Benefits of Daratumumab Combination in MRD-Postitive Multiple Myeloma

7 months ago

Larry Anderson, MD, PhD

Stephen Lam Chan, MBBS, MD (CUHK), FRCP,

1:04

RFS Outcomes With Adjuvant Pembrolizumab vs Placebo After Complete Radiological Response in HCC

7 months ago

Stephen Lam Chan, MBBS, MD

1:08

Hahn Highlights The Promise of Angiogenesis Targeted Therapies in RCC

7 months ago

Andrew W. Hahn, MD

0:21

Hirbe Previews Exciting Progress With Predictive Biomarker Research at SNO 2025

8 months ago

Angela C. Hirbe, MD, PhD

0:25

Schaff Spotlights Key Research in Leptomeningeal Metastases at SNO 2025

8 months ago

Lauren Shaff, MD

1:38

20th Annual New York Lung Cancers Symposium

9 months ago

Benjamin Herzberg, MD(+3 more)

0:57

Unpacking Data From the Phase 3 ROSELLA Study

9 months ago

Vanda Salutari, MD

0:32

The Significance of OptiTROP-Lung04 for TROP-2 ADCs in Lung Cancer

9 months ago

Pasi A. Jänne, MD, PhD

1:34

Precision Strategies and Targeted Combinations in GU Oncology From ESMO 2025

9 months ago

Andrea Necchi, MD(+1 more)

1:32

Breaking Down the Surgical Management of Known Metastatic Cancer

9 months ago

Maurie Markman, MD

1:03

The Multidisciplinary Use of Radiation, Systemic Therapy, and Surgery in Oncology

9 months ago

Maurie Markman, MD

1:41

Examining the Role of Taxpayer-Funded Clinical Trials in Cancer Care

9 months ago

Primo N. Lara Jr, MD

0:32

Unpacking the Phase 3 KEYNOTE-905/EV-303 Trial

9 months ago

Daniel P. Petrylak, MD

0:52

The Role of AI for Oncology Insurance Prior Authorization Processes

9 months ago

Kate Baker, MD, MMHC

Video Shorts

Trending on OncLive

FDA Approves Rituximab Biosimilar for Hematologic Malignancies

Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC

Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026

Emerging Maintenance Strategies May be the Key to Extending Survival in ES-SCLC

Phase 1 Data Set the Stage for Further Exploration of Cevostamab in R/R Myeloma